Search
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
V590
go.drugbank.com/drugs/DB16437ExperimentalMerck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786). … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].
Phleum pratense pollen
go.drugbank.com/drugs/DB10394ApprovedInvestigationalPhleum pratense pollen allergenic extract is used in allergenic testing.
Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen MixProducts: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADETMK-4721
go.drugbank.com/drugs/DB05933InvestigationalMK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients
Telcagepant
go.drugbank.com/drugs/DB12228InvestigationalIt is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. … Telcagepant has been investigated for the treatment of Migraine.
Molibresib
go.drugbank.com/drugs/DB16239InvestigationalMolibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects
CVT-6883
go.drugbank.com/drugs/DB05936ExperimentalCVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation
Categories: Adenosine A2 Receptor AntagonistsLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.
P-113D
go.drugbank.com/drugs/DB04987ExperimentalP-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva. It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.
Synonyms: D-PEPTIDE OF THE SEQUENCE AKRHHGYKRKFH - NH2